Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter italian cohort study

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 997-1002

  De Nunzio, Cosimo ^a   Albisinni, Simone ^a   Freedland, Stephen J ^b   Miano, Lucio ^a   Cindolo, Luca ^d   Finazzi Agrò, Enrico ^c   Autorino, Riccardo ^e   De Sio, Marco ^e   Schips, Luigi ^d   Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d Ospedale Padre Pio da Pietrelcina   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Abdominal obesity; Body mass index; Gleason score; Prostate biopsy; Prostate cancer; Waist circumference

Indexed keywords

ABDOMINAL OBESITY; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER GRADING; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY; WAIST CIRCUMFERENCE;

ABDOMINAL OBESITY; BODY MASS INDEX; GLEASON SCORE; PROSTATE BIOPSY; PROSTATE CANCER; WAIST CIRCUMFERENCE;

AGED; BIOPSY; BODY MASS INDEX; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; OBESITY, ABDOMINAL; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL; WAIST CIRCUMFERENCE;

EID: 84884674779     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.08.007     Document Type: Article

References (34)

1. Berghofer A., Pischon T., Reinhold T., et al. Obesity prevalence from a European perspective: A systematic review. BMC Public Health 2008, 8:200.
2. Freedland S.J., Wen J., Wuerstle M., et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008, 72:1102-1105.
3. Freedland S.J., Banez L.L., Sun L.L., et al. Obese men have higher-grade and larger tumors: An analysis of the Duke prostate center database. Prostate Cancer Prostatic Dis 2009, 12:259-263.
4. Jayachandran J., Banez L.L., Aronson W.J., et al. Obesity as a predictor of adverse outcome across black and white race: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2009, 115:5263-5271.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
6. Rodriguez C., Patel A.V., Calle E.E., et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001, 10:345-353.
7. Ma J., Li H., Giovannucci E., et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008, 9:1039-1047.
8. Isbarn H., Jeldres C., Budaus L., et al. Effect of body mass index on histopathologic parameters: Results of large European contemporary consecutive open radical prostatectomy series. Urology 2009, 73:615-619.
9. Chun F.K., Briganti A., Graefen M., et al. Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. Eur J Cancer 2007, 43:375-382.
10. Gallina A., Karakiewicz P.I., Hutterer G.C., et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer 2007, 121:791-795.
11. Dimitropoulou P., Martin R.M., Turner E.L., et al. Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study. Br J Cancer 2011, 104:875-881.
12. Pischon T., Boeing H., Weikert S., et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008, 17:3252-3261.
13. De Nunzio C., Freedland S.J., Miano R., et al. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011, 71:1492-1498.
14. Kassi E., Pervanidou P., Kaltsas G., et al. Metabolic syndrome: Definitions and controversies. BMC Med 2011, 9:48-61.
15. Andriole G.L., Bostwick D.G., Brawley O.W., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-1202.
16. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
17. Buschemeyer W.C., Freedland S.J. Obesity and prostate cancer: Epidemiology and clinical implications. Eur Urol 2007, 52:331-343.
18. Fowke J.H., Motley S.S., Cookson M.S., et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2007, 10:137-142.
19. Schuurman A.G., Goldbohm R.A., Dorant E., et al. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 2000, 151:541-549.
20. Nilsen T.I., Vatten L.J. Anthropometry and prostate cancer risk: A prospective study of 22,248 Norwegian men. Cancer Causes Control 1999, 10:269-275.
21. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004, 22:439-445.
22. Rodriguez C., Freedland S.J., Deka A., et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:63-69.
23. Dahle S.E., Chokkalingam A.P., Gao Y.T., et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002, 168:599-604.
24. Hammarsten J., Hogstedt B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001, 39:151-158.
25. Freedland S.J., Terris M.K., Platz E.A., et al. Body mass index as a predictor of prostate cancer: Development vs. detection on biopsy. Urology 2005, 66:108-113.
26. Baillargeon J., Pollock B.H., Kristal A.R., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005, 103:1092-1095.
27. Ku J.H., Kim M.E., Lee N.K., et al. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-aged men. Urology 2003, 61:132-136.
28. Werny D.M., Thompson T., Saraiya M., et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007, 16:70-76.
29. Banez L.L., Hamilton R.J., Partin A.W., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007, 298:2275-2280.
30. Stattin P., Soderberg S., Hallmans G., et al. Leptin is associated with increased prostate cancer risk: A nested case-referent study. J Clin Endocrinol Metab 2001, 86:1341-1345.
31. Gade-Andavolu R., Cone L.A., Shu S., et al. Molecular interactions of leptin and prostate cancer. Cancer J 2006, 12:201-206.
32. Freedland S.J., Sokoll L.J., Platz E.A., et al. Association between serum adiponectin, and pathologic stage and grade in men undergoing radical prostatectomy. J Urol 2005, 174:1266-1270.
33. Goktas S., Yilmaz M.I., Caglar K., et al. Prostate cancer and adiponectin. Urology 2005, 65:1168-1172.
34. De Nunzio C.K.G., Marberger M., Montironi R., et al. The controversial relationship between BPH and prostate cancer: The role of inflammation. Eur Urol 2011, 30:106-117.